ALCAM/CD166 is a TGF-b-responsive marker and functional regulator of prostate cancer metastasis to bone

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1404-1415

  Hansen, Amanda G ^a,b   Arnold, Shanna A ^a   Jiang, Ming ^c,f   Palmer, Trenis D ^a   Ketova, Tatiana ^a   Merkel, Alyssa ^a,e   Pickup, Michael ^b   Samaras, Susan ^a   Shyr, Yu ^d   Moses, Harold L ^b   Hayward, Simon W ^b,c   Sterling, Julie A ^a,b,e   Zijlstra, Andries ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Departments of Systems Biology   (United States)

^c Intermountain Health Care   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

^f NANTONG MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CASPASE 3; KI 67 ANTIGEN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADVANCED CANCER; ALCAM GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CELL LYSATE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE SILENCING; GENETIC ANALYSIS; IN VIVO STUDY; MALE; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ADAM PROTEINS; ANTIGENS, CD; BONE AND BONES; CASPASE 3; CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR MICROENVIRONMENT; DISEASE PROGRESSION; FETAL PROTEINS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 84896526311     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1296     Document Type: Article

References (42)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
3. Jin J-K, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 2011;128:2545-61.
4. Palmer TD, Ashby WJ, Lewis JD, Zijlstra A. Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev 2011;63:568-81.
5. van Kempen LC, Nelissen JM, Degen WG, Torensma R, Weidle UH, Bloemers HP, et al. Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem 2001;276:25783-90.
6. Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, et al. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 2007;5:1246-53.
7. Pokutta S, Weis WI. Structure and mechanism of cadherins and catenins in cell-cell contacts. Annu Rev Cell Dev Biol 2007;23:237-61.
8. van Kempen LC, Meier F, Egelad M, Kersten-Niessen MJF, Garbe C, Weidle UH, et al. Truncation of activated cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol 2004;122: 1293-301.
9. Hansen A, Swart GW, Zijlstra A. ALCAM. UCSD Nat Mol Pages 2011 Feb 1. doi:10.1038/mp.a004126.01.
10. Hansen AG, Freeman TJ, Arnold SA, Starchenko A, Jones-Paris CR, Gilger MA, et al. Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. Cancer Res 2013;73: 2955-64.
11. Carbotti G, Orengo AM, Mezzanzanica D, Bagnoli M, Brizzolara A, Emionite L, et al. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer 2012;132:2597-605.
12. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi A-B, Fodstad O, Jiang WG. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 2004;6:R478-87.
13. Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 2008;14:1726-33.
14. Micciche F, Da Riva L, Fabbi M, Pilotti S, Mondellini P, Ferrini S, et al. Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors. PLoS ONE 2011;6:e17141.
15. Minner S, Kraetzig F, Tachezy M, Kilic E, Graefen M, Wilczak W, et al. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol 2011;42:1946-52.
16. Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003;54:34-43.
17. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005;205:359-76.
18. Lunter PC, van Kilsdonk JW, van Beek H, Cornelissen IM, Bergers M, Willems PH, et al. Activated leukocyte cell adhesion molecule (ALCAM/ CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 2005;65:8801-8.
19. Witzel I, Schr̈oder C, M̈uller V, Zander H, Tachezy M, Ihnen M, et al. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis. Oncology 2012; 82:305-12.
20. Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen Y-J, et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-b inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther 2012;23:871-82.
21. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 1989;62:79-87.
22. Ashby WJ, Wikswo JP, Zijlstra A. Magnetically attachable stencils and the non-destructive analysis of the contribution made by the underlying matrix to cell migration. Biomaterials 2012;33:8189-203.
23. Li H, Jiang M, Honorio S, Patrawala L, Jeter CR, Calhoun-Davis T, et al. Methodologies in assaying prostate cancer stem cells. Methods Mol Biol 2009;568:85-138.
24. Park SI, Kim S-J, McCauley LK, Gallick GE. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol 2010;Chapter 14:Unit14.15.
25. Campbell JP, merkel AR, Masood-Campbell SK, Elefteriou F, Sterling JA. Models of bone metastasis. J Vis Exp 2012;e4260.
26. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
27. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS ONE 2008;3:e2318.
28. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008;68:3645-54.
29. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010;28:1248-50.
30. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, et al. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res 1996;56:44-8.
31. Tachezy M, Zander H, Gebauer F, Marx A, Kaifi JT, Izbicki JR, et al. Activated leukocyte cell adhesion molecule (CD166)-Its prognostic power for colorectal cancer patients. J Surg Res 2012;177:e15-20.
32. Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, Vashist YK, et al. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer 2012;131:396-405.
33. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, et al. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 2008;28: 5605-20.
34. Soond SM, Everson B, Riches DWH, Murphy G. ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 2005;118:2371-80.
35. Ott GR, Asakawa N, Lu Z, Anand R, Liu R-Q, Covington MB, et al. Potent, exceptionally selective, orally bioavailable inhibitors of TNFalpha converting enzyme (TACE): novel 2-substituted-1H-benzo[ d]imidazol-1-yl)methyl)benzamide P10 substituents. Bioorg Med Chem Lett 2008;18:1577-82.
36. Wang Y, Xue H, Cutz J-C, Bayani J, Mawji NR, Chen WG, et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005;85: 1392-404.
37. Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 2008;151:122-8.
38. Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin M-F, et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol 2003;23:1365-71.
39. Masedunskas A, King JA, Tan F, Cochran R, Stevens T, Sviridov D, et al. Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett 2006;580:2637-45.
40. Jezierska A, Matysiak W, Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit 2006; 12:BR263-73.
41. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 2008;27:41-55.
42. Buijs JT, Que I, L̈owik CW, Papapoulos SE, van der Pluijm G. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009;44:380-6.